The triple agonist that showed 24.2% weight loss in Phase 2 is now in pivotal Phase 3 trials. Here's what the TRIUMPH data shows, where the FDA review stands, and the realistic approval timeline.
In July 2023, a paper published in the New England Journal of Medicine stopped the obesity medicine world in its tracks. A drug called retatrutide — developed by Eli Lilly, formally designated LY3437943 — had just produced a 24.2% mean reduction in body weight over 48 weeks in a Phase 2 randomized controlled trial. That number, 24.2%, had never been seen in a single pharmacological agent before. For context: semaglutide 2.4 mg (Wegovy), which itself transformed obesity medicine, achieves around 15%. Tirzepatide (Zepbound), which most longevity physicians now consider the most powerful approved option, reaches 20–22%. Retatrutide pushed past both — and Phase 3 was next.
Two years later, in 2026, the TRIUMPH Phase 3 program is reading out. This article covers what we know, what the data shows, where the FDA review stands, and how to think about retatrutide's place in your longevity strategy while you wait.
Retatrutide is a once-weekly injectable peptide that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. It is the first unimolecular triple agonist to reach Phase 3 clinical trials in humans.
Each receptor activation contributes something distinct:
GLP-1 receptor: The foundational mechanism shared with semaglutide (Ozempic, Wegovy). GLP-1 reduces appetite through hypothalamic signaling, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. The GLP-1 component accounts for the drug's appetite-suppressing effects and much of its glucose-lowering activity.